Skip to content

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04820881
Enrollment
60
Registered
2021-03-29
Start date
2021-10-01
Completion date
2024-09-30
Last updated
2022-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodegenerative Diseases

Brief summary

This grant award entitled, Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury (hereafter, Neurovascular Study), aims to determine if neurovascular contributors to neurodegeneration can serve as markers of the emergence or progression of degenerative processes after traumatic brain injury in middle-aged and older adults.

Detailed description

This grant award entitled, Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury (hereafter, Neurovascular Study), aims to determine if neurovascular contributors to neurodegeneration can serve as markers of the emergence or progression of degenerative processes after traumatic brain injury in middle-aged and older adults. Primary outcomes are cerebrovascular reactivity (CVR), as measured by functional Magnetic Resonance Imaging (MRI) Blood Oxygen Level Dependent (BOLD) and cerebral metabolic rate of oxygen (CMRO2) as assessed by the novel MRI sequence called, T-2 Relaxation-Under-Spin-Tagging (TRUST). After the baseline primary endpoints are acquired, a single dose of sildenafil 50mg will be given to assess for the effects of a hypercapnia task on CVR and CMRO2. Other outcomes measured include additional imaging sequences (diffusion, ASL), volumetric analysis, and neuropsychological tests.

Interventions

None listed

Sponsors

Henry M. Jackson Foundation for the Advancement of Military Medicine
CollaboratorOTHER
Washington D.C. Veterans Affairs Medical Center
Lead SponsorFED

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

(All Participants): * Ages 50-80 years * Eligible for Washington, DC Veterans Affairs Medical Center (VAMC) research participation * Capacity to provide consent to participate in research (assessment made by study neurologist and PI) * Ability to read and write English Inclusion Criteria Case Group: • History of traumatic brain injury of sufficient severity to have resulted in medical attention ascertained via the Ohio State University TBI Identification Questionnaire (OSU TBI-ID). TBI defined by Departments of Defense/Veterans Affairs (DoD/VA) criteria. Inclusion Criteria Control Group: • No history of traumatic brain injury of sufficient severity to have resulted in medical attention ascertained via the OSU TBI-ID, and no TBI based upon DOD/VA criteria.

Exclusion criteria

(All Participants): * History of penetrating brain injury * History or evidence of disabling neurological or psychiatric condition such as epilepsy (besides posttraumatic epilepsy), multiple sclerosis, hypoxic-ischemic encephalopathy, encephalitis, or schizophrenia * History or evidence of cortical or subcortical stroke * History or evidence of diabetes mellitus requiring therapy (Hemoglobin A1c \> 9.0% for purposes of this study) * History or evidence of uncontrolled hyperlipidemia. For the purposes of this study, hyperlipidemia will be defined as total cholesterol of 230 in the presence of either or both diabetes and hypertension and 300 in the absence of both of these conditions. Statin therapy with normal cholesterol levels is allowed. * History or evidence of uncontrolled hypertension (defined as systolic pressure \> 160 and/or diastolic pressure \> 110 mmHg), or hypotension (systolic pressure \< 110 and/or diastolic pressure \< 65 mmHg). Hypertension controlled with a single anti- hypertensive medication is allowed. * Untreated atrial fibrillation * Active tobacco use * MRI incompatibility * If a participant is currently or has previously taken a phosphodiesterase inhibitor (PDESi), then a two week washout period is required immediately prior to the evaluation visit. * Use of nitrates

Design outcomes

Primary

MeasureTime frameDescription
Cerebrovascular Reactivity (CVR)Two yearsCerebrovascular reactivity is the change in cerebral blood flow in response to a vasoactive stimulus, in this case hypercapnia induced by 5% carbon dioxide as measured by MRI BOLD
Cerebral Metabolic Rate of Oxygen (CMRO2)Two yearsCerebral metabolic rate of oxygen represents the amount of oxygen consumed as measured by the MRI T2-Relaxation-Under-Spin-Tagging (TRUST) sequence.

Countries

United States

Contacts

Primary ContactJulie C Chapman, PsyD
Julie.Chapman@va.gov202-745-8000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026